Industry
Biotechnology
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Loading...
Open
5.66
Mkt cap
230M
Volume
87K
High
5.66
P/E Ratio
-9.61
52-wk high
5.74
Low
5.31
Div yield
N/A
52-wk low
2.14
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 12:27 pm
Portfolio Pulse from Avi Kapoor
October 07, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 4:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:58 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:58 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 3:19 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 12:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.